Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China

prnasiaJuly 13, 2021

Tag: Ascletis , ASC42 , Gannex , FXR agonist , CHB

PharmaSources Customer Service